CPIX
Cumberland Pharmaceuticals Inc.

2,574
Mkt Cap
$29.61M
Volume
125,663.00
52W High
$7.25
52W Low
$1.04
PE Ratio
-8.58
CPIX Fundamentals
Price
$2.00
Prev Close
$1.98
Open
$1.99
50D MA
$3.18
Beta
0.50
Avg. Volume
32,735.17
EPS (Annual)
-$0.4609
P/B
1.15
Rev/Employee
$416,131.26
Loading...
Loading...
News
all
press releases
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH
CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH CUMBERLAND PHARMACEUTICALS REPORTS 12% YEAR-TO-DATE REVENUE GROWTH PR Newswire NASHVILLE, Tenn., Nov. 4, 2025 NASHVILLE, Tenn., Nov...
PR Newswire·8d ago
News Placeholder
More News
News Placeholder
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE CUMBERLAND PHARMACEUTICALS TO ANNOUNCE Q3 2025 FINANCIAL RESULTS & COMPANY UPDATE PR Newswire NASHVILLE, Tenn., Oct...
PR Newswire·15d ago
News Placeholder
CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC.
CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC. CUMBERLAND PHARMACEUTICALS' VIBATIV ADDED TO NATIONAL GROUP PURCHASING AGREEMENT WITH PREMIER, INC...
PR Newswire·30d ago
News Placeholder
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn., Feb. 25, 2025 NASHVILLE, Tenn...
PR Newswire·9mo ago
News Placeholder
VIBATIV RECEIVES MARKETING APPROVAL IN CHINA
VIBATIV RECEIVES MARKETING APPROVAL IN CHINA VIBATIV RECEIVES MARKETING APPROVAL IN CHINA PR Newswire NASHVILLE, Tenn. and SHANGHAI, Feb. 18, 2025 Vibativ is a life-saving antibiotic for pneumonia...
PR Newswire·9mo ago
News Placeholder
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease
Cumberland Pharmaceuticals Announces Breakthrough Results from the Phase 2 FIGHT DMD Trial in Duchenne Muscular Dystrophy Heart Disease Cumberland Pharmaceuticals Announces Breakthrough Results from...
PR Newswire·9mo ago
News Placeholder
Cumberland Pharma Stock Hits 16-Month High After FDA Approves Liver Drug Regimen: Retail’s Thrilled
The newly approved regimen combines the first two standard doses into a single, slower infusion, simplifying administration and improving patient outcomes, according to experts.
Stocktwits·11mo ago
News Placeholder
FDA APPROVES ACETADOTE sNDA
FDA APPROVES ACETADOTE sNDA FDA APPROVES ACETADOTE sNDA PR Newswire NASHVILLE, Tenn., Dec. 9, 2024 - New Dosing Regimen Simplifies Administration - NASHVILLE, Tenn., Dec. 9, 2024 /PRNewswire...
PR Newswire·11mo ago
News Placeholder
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update PR Newswire...
PR Newswire·1y ago
News Placeholder
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND RARE PEDIATRIC DISEASE DESIGNATIONS FOR NEW TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY CUMBERLAND PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG AND...
PR Newswire·1y ago

Latest CPIX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.